MarketInOut Stock Screener Log In | Sign Up

Ardelyx Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Ardelyx Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization782.31 mln
Float239 mln
Earnings Date11/03/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-2.44
Borderline

1-Year Forecast

12.80
Transformational upside

Relative Strength

36 / 100
Underperforming

Debt / Equity

1.72
High leverage

Pre-Tax Margin

-12%
Loss-making

Business Description

Ardelyx is a pharmaceutical company based in Waltham, Massachusetts, that creates and sells treatments for conditions that have few or no existing solutions, both in the United States and abroad. Its two main products are IBSRELA, used to treat irritable bowel syndrome with constipation, and XPHOZAH, which helps control phosphorus levels in adults with chronic kidney disease who are on dialysis. Founded in 2007 under the name Nteryx, the company rebranded as Ardelyx in 2008.

Key Fundamentals

EPS-0.23
ROE-36.72
RPS1.84
ROIC-20.07
ROA-10.98
Interest Cover-1.29
EBITDA, mln-23.43
EV / EBITDA-30.68
EV / EBIT-26.85
Revenue, mln451
EV / Revenue1.59

Quote Details

Last 3.03
Change -0.07 (-2.26%)
Open 3.09
Volume 3,625,517
Turnover 10,985,316
Average Volume 4,387,631

Financial Ratios

Pre-Tax Profit Margin-12
Leverage Ratio3.86
Current Ratio3.34
Price / Book5.02
Price / Tangible Book5.00
Debt / Equity1.72
Price / Sales1.63

Financial Strength

Altman Z-Score-0.1
Piotroski F-Score 4 / 9
Beneish M-Score-2.44
1-Year Target Price12.80
Short Ratio6.65
Short % of Float11.96

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.62% 31 / 100   
1 Month -10.36% 29 / 100   
2 Months -40.12% 12 / 100   
6 Months -55.96% 11 / 100   
1 Year -38.91% 23 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog